USANA Health Sciences (NYSE:USNA) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $29.54 and traded as high as $30.62. USANA Health Sciences shares last traded at $30.57, with a volume of 109,330 shares traded.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $36.00.

USANA Health Sciences Stock Up 2.2%

The company has a market cap of $558.51 million, a P/E ratio of 16.98, a price-to-earnings-growth ratio of 0.95 and a beta of 0.64. The company's 50-day moving average is $31.00 and its two-hundred day moving average is $29.54.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million during the quarter, compared to analyst estimates of $225.20 million. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. On average, analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Insider Activity

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of the company's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Mulham Mulham sold 3,515 shares of the company's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider directly owned 9,260 shares in the company, valued at approximately $280,207.60. This trade represents a 27.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. US Bancorp DE lifted its holdings in shares of USANA Health Sciences by 13.1% in the first quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of USANA Health Sciences by 7.1% in the first quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock worth $248,000 after buying an additional 606 shares in the last quarter. Creative Planning lifted its holdings in shares of USANA Health Sciences by 3.2% in the second quarter. Creative Planning now owns 20,051 shares of the company's stock worth $612,000 after buying an additional 613 shares in the last quarter. Quantbot Technologies LP lifted its holdings in shares of USANA Health Sciences by 19.5% in the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after buying an additional 646 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of USANA Health Sciences by 339.6% in the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after buying an additional 771 shares in the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.